- Home
- ORKA vs ERII Comparison
ORKA vs ERII Comparison
Compare ORKA & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- ERII
- Stock Information
- Founded
- ORKA 2004
- ERII 1992
- Country
- ORKA United States
- ERII United States
- Employees
- ORKA N/A
- ERII N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ERII Industrial Machinery/Components
- Sector
- ORKA Health Care
- ERII Technology
- Exchange
- ORKA Nasdaq
- ERII Nasdaq
- Market Cap
- ORKA 580.3M
- ERII 762.9M
- IPO Year
- ORKA N/A
- ERII 2008
- Fundamental
- Price
- ORKA $16.18
- ERII $14.55
- Analyst Decision
- ORKA Strong Buy
- ERII Buy
- Analyst Count
- ORKA 6
- ERII 4
- Target Price
- ORKA $40.83
- ERII $18.75
- AVG Volume (30 Days)
- ORKA 190.4K
- ERII 369.5K
- Earning Date
- ORKA 11-12-2025
- ERII 10-29-2025
- Dividend Yield
- ORKA N/A
- ERII N/A
- EPS Growth
- ORKA N/A
- ERII 25.10
- EPS
- ORKA N/A
- ERII 0.43
- Revenue
- ORKA N/A
- ERII $141,775,000.00
- Revenue This Year
- ORKA N/A
- ERII $6.16
- Revenue Next Year
- ORKA N/A
- ERII $13.06
- P/E Ratio
- ORKA N/A
- ERII $34.28
- Revenue Growth
- ORKA N/A
- ERII 6.19
- 52 Week Low
- ORKA $5.49
- ERII $10.86
- 52 Week High
- ORKA $31.13
- ERII $20.27
- Technical
- Relative Strength Index (RSI)
- ORKA 57.31
- ERII 62.76
- Support Level
- ORKA $14.67
- ERII $14.20
- Resistance Level
- ORKA $18.50
- ERII $14.65
- Average True Range (ATR)
- ORKA 1.11
- ERII 0.37
- MACD
- ORKA -0.01
- ERII 0.01
- Stochastic Oscillator
- ORKA 40.36
- ERII 99.07
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.